Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 7/20 | 0.67 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.67 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.67 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.67 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CNOT7 | Q9UIV1 | 4/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10693202 | 0.96 | PDE4A (0.63) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL10695023 | 0.96 | PDE4A (0.63) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL10695142 | 0.92 | PDE4A (0.68) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL10695010 | 0.92 | PDE4A (0.68) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL10696905 | 0.91 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL8697287 | 0.90 | PDE4A (0.67) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL8696632 | 0.90 | PDE4A (0.67) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL8696628 | 0.90 | PDE4A (0.67) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL10694067 | 0.88 | SMN1; SMN2 (0.67) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL11613478 | 0.85 | PDE4A (0.62) | PDE4APDE4BPDE4CPDE4DADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0485495-A1 | USE OF XANTHINE-DERIVATIVES AS INHIBITORS OF INDUCED BLOOD EOSINOPHILIA | Beecham Group p.l.c. (GB) | 1992-05-20 | — | — | EP | claimed |
| EP-0421587-A2 | Xanthine derivatives used in asthma | Beecham Group p.l.c. (GB) | 1991-04-10 | — | — | EP | claimed |
| WO-1991001730-A2 | USE OF XANTHINE-DERIVATIVES AS INHIBITORS OF INDUCED BLOOD EOSINOPHILIA | BEECHAM GROUP PLC (GB) | 1991-02-21 | — | — | WO | claimed |
| US-4784999-A | Novel treatment | BEECHAM WUELFING GMBH & CO. KG (DE) | 1988-11-15 | — | — | US | claimed |
| EP-0267676-A2 | Use of 1,3-di-n-butyl-7-(2-oxypropyl) xanthine in the treatment of cerebrovascular or cerebral senility associated disorders, peripheral vascular disease and proliferative skin diseases | Beecham Wuelfing GmbH & Co KG (DE) | 1988-05-18 | — | — | EP | claimed |
| EP-1776108-A1 | ENOXIMONE FORMULATIONS AND THEIR USE IN THE TREATMENT OF PDE-III MEDIATED DISEASES | MYOGEN, INC. (US) | 2007-04-25 | — | — | EP | disclosed |
| US-20060292213-A1 | Enoximone formulations and their use in the treatment of PDE-III mediated diseases | MYOGEN, INC. | 2006-12-28 | — | — | US | disclosed |
| WO-2006007213-A1 | ENOXIMONE FORMULATIONS AND THEIR USE IN THE TREATMENT OF PDE-III MEDIATED DISEASES | MYOGEN, INC. (US) | 2006-01-19 | — | — | WO | disclosed |
| EP-0389282-B1 | Xanthinederivatives, process for their preparation and their pharmaceutical use | SMITHKLINE BEECHAM PHARMA GMBH (DE) | 2002-02-20 | — | — | EP | disclosed |
| US-5919474-A | Transurethral administration of vasoactive agents to treat peripheral vascular disease, related vascular diseases, and vascular impotence associated therewith | VIVUS, INC. (US) | 1999-07-06 | — | — | US | disclosed |
| EP-0421587-A2 | Xanthine derivatives used in asthma | Beecham Group p.l.c. (GB) | 1991-04-10 | — | — | EP | disclosed |
| EP-0267676-A3 | USE OF 1,3-DI-N-BUTYL-7-(2-OXYPROPYL) XANTHINE IN THE TREATMENT OF CEREBROVASCULAR OR CEREBRAL SENILITY ASSOCIATED DISORDERS, PERIPHERAL VASCULAR DISEASE AND PROLIFERATIVE SKIN DISEASES | Beecham Wuelfing GmbH & Co KG (DE) | 1990-04-04 | — | — | EP | disclosed |
| EP-0267676-A3 | USE OF 1,3-DI-N-BUTYL-7-(2-OXYPROPYL) XANTHINE IN THE TREATMENT OF CEREBROVASCULAR OR CEREBRAL SENILITY ASSOCIATED DISORDERS, PERIPHERAL VASCULAR DISEASE AND PROLIFERATIVE SKIN DISEASES | Beecham Wuelfing GmbH & Co KG (DE) | 1990-04-04 | — | — | EP | disclosed |
| US-4784999-A | Novel treatment | BEECHAM WUELFING GMBH & CO. KG (DE) | 1988-11-15 | — | — | US | disclosed |
| US-4784999-A | Novel treatment | BEECHAM WUELFING GMBH & CO. KG (DE) | 1988-11-15 | — | — | US | disclosed |
| EP-0267676-A2 | Use of 1,3-di-n-butyl-7-(2-oxypropyl) xanthine in the treatment of cerebrovascular or cerebral senility associated disorders, peripheral vascular disease and proliferative skin diseases | Beecham Wuelfing GmbH & Co KG (DE) | 1988-05-18 | — | — | EP | disclosed |
| EP-0267676-A2 | Use of 1,3-di-n-butyl-7-(2-oxypropyl) xanthine in the treatment of cerebrovascular or cerebral senility associated disorders, peripheral vascular disease and proliferative skin diseases | Beecham Wuelfing GmbH & Co KG (DE) | 1988-05-18 | — | — | EP | disclosed |
| EP-0267676-A2 | Use of 1,3-di-n-butyl-7-(2-oxypropyl) xanthine in the treatment of cerebrovascular or cerebral senility associated disorders, peripheral vascular disease and proliferative skin diseases | Beecham Wuelfing GmbH & Co KG (DE) | 1988-05-18 | — | — | EP | disclosed |